Daiwa Securities Group Inc. reduced its position in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 21.8% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 151,447 shares of the biopharmaceutical company’s stock after selling 42,100 shares during the quarter. Daiwa Securities Group Inc.’s holdings in Bristol-Myers Squibb were worth $9,281,000 at the end of the most recent quarter.
A number of other hedge funds have also recently bought and sold shares of the stock. Advisor Partners LLC raised its stake in shares of Bristol-Myers Squibb by 6.9% in the third quarter. Advisor Partners LLC now owns 36,961 shares of the biopharmaceutical company’s stock worth $2,356,000 after purchasing an additional 2,382 shares during the last quarter. Oppenheimer & Co. Inc. raised its stake in shares of Bristol-Myers Squibb by 2.5% in the second quarter. Oppenheimer & Co. Inc. now owns 358,509 shares of the biopharmaceutical company’s stock worth $19,976,000 after purchasing an additional 8,813 shares during the last quarter. Israel Discount Bank of New York raised its stake in shares of Bristol-Myers Squibb by 31.8% in the second quarter. Israel Discount Bank of New York now owns 10,515 shares of the biopharmaceutical company’s stock worth $586,000 after purchasing an additional 2,540 shares during the last quarter. Van ECK Associates Corp raised its stake in shares of Bristol-Myers Squibb by 0.7% in the third quarter. Van ECK Associates Corp now owns 791,275 shares of the biopharmaceutical company’s stock worth $50,436,000 after purchasing an additional 5,451 shares during the last quarter. Finally, Aperio Group LLC raised its stake in shares of Bristol-Myers Squibb by 12.7% in the third quarter. Aperio Group LLC now owns 854,457 shares of the biopharmaceutical company’s stock worth $54,463,000 after purchasing an additional 96,561 shares during the last quarter. 71.55% of the stock is currently owned by institutional investors and hedge funds.
In other news, Director Theodore R. Samuels II acquired 4,000 shares of Bristol-Myers Squibb stock in a transaction on Friday, December 15th. The stock was acquired at an average cost of $62.30 per share, with a total value of $249,200.00. Following the completion of the acquisition, the director now owns 22,000 shares in the company, valued at $1,370,600. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 0.23% of the stock is currently owned by corporate insiders.
Bristol-Myers Squibb Co (NYSE BMY) opened at $66.68 on Wednesday. The stock has a market capitalization of $110,117.72, a P/E ratio of 113.02, a PEG ratio of 2.07 and a beta of 0.98. The company has a quick ratio of 1.43, a current ratio of 1.55 and a debt-to-equity ratio of 0.59. Bristol-Myers Squibb Co has a twelve month low of $51.56 and a twelve month high of $70.05.
Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.01. The company had revenue of $5.45 billion during the quarter, compared to analyst estimates of $5.35 billion. Bristol-Myers Squibb had a return on equity of 35.43% and a net margin of 4.85%. Bristol-Myers Squibb’s quarterly revenue was up 3.9% on a year-over-year basis. During the same period in the prior year, the company posted $0.63 earnings per share. analysts anticipate that Bristol-Myers Squibb Co will post 3.2 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, May 1st. Stockholders of record on Friday, April 6th will be issued a $0.40 dividend. This represents a $1.60 annualized dividend and a dividend yield of 2.40%. The ex-dividend date of this dividend is Thursday, April 5th. Bristol-Myers Squibb’s dividend payout ratio is presently 271.19%.
TRADEMARK VIOLATION WARNING: This story was posted by American Banking News and is owned by of American Banking News. If you are reading this story on another publication, it was copied illegally and reposted in violation of US and international copyright legislation. The legal version of this story can be read at https://www.americanbankingnews.com/2018/03/14/daiwa-securities-group-inc-reduces-position-in-bristol-myers-squibb-co-bmy.html.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.